Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544382 | 0.96 | PDPK1 (0.41) | PDPK1KDM4EARKMT2AADORA3 | |
| SCHEMBL2546824 | 0.80 | LMNA (0.42) | KDM4EARKMT2AALDH1A1POLB | |
| SCHEMBL208797 | 0.78 | GFER (0.42) | KDM4EKMT2AADORA3ADORA2AADORA2B | |
| SCHEMBL20582831 | 0.78 | CYP19A1 (0.41) | KDM4EKMT2AALDH1A1POLBRAB9A | |
| SCHEMBL5539570 | 0.78 | RAB9A (0.41) | KDM4EKMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL695005 | 0.78 | KDM4E (0.41) | KDM4EARKMT2AALDH1A1POLB | |
| SCHEMBL355117 | 0.78 | CYP2A6 (0.53) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14562911 | 0.77 | NPC1 (0.39) | PDPK1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL694798 | 0.77 | KDM4E (0.47) | KDM4EKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7507911 | 0.77 | CYP19A1 (0.42) | KMT2AALDH1A1POLBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 676 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| EP-3600312-B1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-17 | — | — | EP | claimed |
| CN-110520127-B | Piperidinyl-substituted and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | 武田药品工业株式会社 | 2023-05-16 | — | — | CN | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| US-10959986-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-30 | — | — | US | claimed |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | claimed |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA CALIFORNIA, INC. | 2020-12-03 | — | — | US | claimed |
| EP-3720858-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| CN-111699189-A | Modulators of beta-3 adrenergic receptors useful for the treatment or prevention of heart failure and disorders associated therewith | 艾尼纳制药公司 | 2020-09-22 | — | — | CN | claimed |
| US-4824833-A | ANTIDIABETIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1989-04-25 | — | — | US | claimed |
| CN-1003712-B | Process for preparing 6- (1-acyl-1-hydroxymethyl or acetoxymethyl) penicillanic acid derivatives | 美国辉瑞有限公司 | 1989-03-29 | — | — | CN | claimed |
| EP-0301813-A1 | Naphthalenepropionic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-02-01 | — | — | EP | claimed |
| EP-0146370-B1 | IMIDAZOQUINOLINES CONTAINING OTHER HETEROCYCLIC GROUPS | JOHN WYETH & BROTHER LIMITED (GB) | 1988-10-19 | — | — | EP | claimed |
| EP-0283036-A1 | Benzoxazine derivatives and processes for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1988-09-21 | — | — | EP | claimed |
| US-4762921-A | 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1988-08-09 | — | — | US | claimed |
| US-4675186-A | 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1987-06-23 | — | — | US | claimed |
| EP-0201221-A1 | 6-(1-acyl-1-hydroxy methyl) penicillanic acid derivatives | PFIZER INC. (US) | 1986-11-12 | — | — | EP | claimed |
| CN-86102736-A | The preparation method and the application thereof of 6-(1-acyl group-1-methylol) penicillanic acid derivative | — | 1986-10-15 | — | — | CN | claimed |
| EP-0146370-A2 | Imidazoquinolines containing other heterocyclic groups | JOHN WYETH & BROTHER LIMITED (GB) | 1985-06-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | PDPK1 2435/4885KDM4E 4728/4885AR 799/4885 |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | GPR6, GPR3, GPR68 | PDPK1 2316/4885KDM4E 2204/4885AR 267/4885 |
| US-10959986-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | PDPK1 595/4885KDM4E 485/4885AR 1544/4885 |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | PDPK1 2580/4885KDM4E 4739/4885AR 808/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | PDPK1 2580/4885KDM4E 4739/4885AR 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.